Elderly Metastatic Breast Cancer Population Clinical Trial
Official title:
Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group
| Verified date | November 2022 |
| Source | European Organisation for Research and Treatment of Cancer - EORTC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast cancer. Chemotherapy however is associated with significant side-effects and can impact on Quality of Life and functionality in older patients. The investigators aim to establish HER2 targeted regimens with minimal toxicity in order to delay or even avoid the use of classical chemotherapy because of competing risks of death in this frail/elderly patient group.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | November 2022 |
| Est. primary completion date | March 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 60 Years and older |
| Eligibility | Inclusion Criteria: - Patients with histologically proven HER-2 positive - Newly diagnosed or recurrent (after surgery) stage IV disease (TNM/AJCC v.7). - Patients must have measurable (RECIST v. 1.1) or evaluable disease - Performance status (PS) 0-3 (WHO) - Age = 70 years of age, or = 60 years old with required number of dependencies - Life expectancy of more than 12 weeks - Previous adjuvant chemotherapy/anti HER-2 therapy after surgery is allowed, given that the time interval from end of previous treatment to initiation of treatment for metastatic disease is = 6 months. - Up to one line of anti-HER therapy (trastuzumab or lapatinib) is allowed in combination with hormone therapy for hormone sensitive metastatic breast cancer. - Adequate organ function - Before patient randomization, written informed consent must be given according to ICH/GCP, and national/local regulations. Exclusion Criteria: - No brain metastases that are untreated, symptomatic, or require steroids to control symptoms; or any radiation, surgery, or other therapy to control symptoms from brain metastases within 2 months prior to the first study treatment. - No prior chemotherapy for metastatic disease is allowed - No prior treatment with pertuzumab is allowed - No history of exposure to the following cumulative doses of anthracyclines: - Doxorubicin or liposomal doxorubicin > 360 mg/m2 - Epirubicin > 720 mg/m2 - Mitoxantrone > 120 mg/m2 - Idarubicin > 90 mg/m2 - If another anthracycline or more than 1 anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin. - No history of palliative radiotherapy within 14 days of randomization - No history of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell or spinocellular carcinoma of the skin - No current uncontrolled hypertension (persistent systolic > 180 mmHg and/or diastolic > 100 mmHg) - No LVEF below 50% - No history of significant cardiac disease defined as: - Symptomatic CHF (NYHA classes II-IV) - High-risk uncontrolled arrhythmias - History of myocardial infarction within 6 months prior to randomization - Clinically significant valvular heart disease - No angina pectoris requiring anti-angina treatment - No peripheral neuropathy of Grade = 3 per NCI CTCAE version 4.0. - No current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus) - No major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment - No history of receiving any investigational treatment within 28 days of randomization - No history of intolerance (including Grade 3-4 infusion reaction) to trastuzumab - No unwillingness or inability to comply with the requirements of the protocol as assessed by the investigator - Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | UZ Antwerpen | Antwerpen | |
| Belgium | Cliniques Universitaires Saint-Luc | Brussels | |
| Belgium | Institut Jules Bordet | Brussels | |
| Belgium | Hopital De Jolimont | Haine St Paul | |
| Belgium | AZ Groeninge Kortrijk | Kortrijk | |
| Belgium | UZ Leuven | Leuven | |
| Belgium | CHU Sart-Tilman | Liège | |
| Belgium | Clinique et Maternité Sainte Elisabeth | Namur | |
| Belgium | AZ Damiaan | Oostende | |
| Belgium | AZ Nikolaas | Sint-Niklaas | |
| France | Centre Georges-Francois-Leclerc | Dijon | |
| France | Centre Oscar Lambret | Lille | |
| France | Hopital Rene Huguenin - Institut Curie | Saint-Cloud | |
| France | Centre Paul Strauss | Strasbourg | |
| Italy | Istituto Europeo Di Oncologia | Milano | |
| Italy | Istituto Oncologico Veneto IRCCS - Ospedale Busonera | Padova | |
| Netherlands | Leiden University Medical Centre | Leiden | |
| Netherlands | VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo | Venlo | |
| Poland | Maria Sklodowska-Curie Memorial Cancer Centre | Warsaw | |
| Portugal | Champalimaud Cancer Center | Lisboa | |
| Portugal | Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. | Lisboa | |
| Sweden | Sahlgrenska Universitetssjukhuet | Goteborg | |
| Sweden | Ryhov County Hospital | Jonkoping | |
| Sweden | Uppsala University Hospital - Akademiska Sjukhuset | Uppsala | |
| Sweden | Vastmanland Centralsjukhuset Vasteras | Vasteras | |
| United Kingdom | Velindre NHS Trust - Velindre Cancer Centre | Cardiff | |
| United Kingdom | NHS Lothian - Western General Hospital | Edinburgh | |
| United Kingdom | NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital | Glasgow | |
| United Kingdom | Peterborough and Stamford Hospitals NHS Foundation Trust - Peterborough City Hospita | Peterboroug | |
| United Kingdom | University Hospital Southampton NHS Foundation Trust - Southampton General Hospital | Southampton |
| Lead Sponsor | Collaborator |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | Hoffmann-La Roche |
Belgium, France, Italy, Netherlands, Poland, Portugal, Sweden, United Kingdom,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Progression free survival rate | 6 months after patients in | ||
| Secondary | Overall survival | |||
| Secondary | Breast cancer specific survival | |||
| Secondary | Tumor response rate as measured by RECIST v1.1 | |||
| Secondary | Evolution of HRQoL as assessed by EORTC QLQ-C30 and ELD 14 | Up to 1 year after treatment start | ||
| Secondary | Evolution of geriatric assessment | Up to 1 year after treatment start | ||
| Secondary | if T-DM1: progression free survival rate | 6 months after start of T-DM1 treatment |